361979-30-8

Usage

Uses

Used in Pharmaceutical Industry:
2-AMINO-1-(4-BENZYL-PIPERAZIN-1-YL)-ETHANONE 2 HCL is used as an intermediate in the synthesis of various drugs and pharmaceuticals for its potential applications in targeting the central nervous system.
Used in Research Chemicals:
2-AMINO-1-(4-BENZYL-PIPERAZIN-1-YL)-ETHANONE 2 HCL is used as a research chemical for the development of new psychoactive substances and the study of its unique structure and pharmacological properties.
Used in Drug Formulation:
2-AMINO-1-(4-BENZYL-PIPERAZIN-1-YL)-ETHANONE 2 HCL is used as a salt form to improve the solubility and stability of the compound in pharmaceutical formulations, enhancing its effectiveness in drug delivery.

InChI:InChI=1/C13H19N3O.2ClH/c14-10-13(17)16-8-6-15(7-9-16)11-12-4-2-1-3-5-12;;/h1-5H,6-11,14H2;2*1H

Upstream product

• 946523-08-6 benzyl ester of [2-(4-benzylpiperazin-1-yl)-2-oxoethyl]carbamic acid 
• 671212-34-3 [2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 56056-37-2 1-benzyl-4-(2-chloroacetyl)piperazine 
• 2759-28-6 1-phenylmethylpiperazine 
• 349423-62-7 2-{2-[4-benzylpiperazin-1-yl]-2-oxoethyl}isoindoline-1,3-dione 

Downstream Products

• 1416064-34-0 C₁₉H₂₉N₃O₂ 
• 1060944-73-1 C₂₄H₃₃N₃O₂ 
• 831251-75-3 C₂₁H₂₄ClN₃O₂ 
• 25443-91-8 N-[2-(4-Benzyl-piperazin-1-yl)-2-oxo-ethyl]-2-phenyl-acetamide 
• 1299424-21-7 C₂₁H₃₁N₃O₂ 
• 744226-61-7 C₂₀H₂₃N₃O₂ 
• 433262-34-1 C₂₀H₂₉N₃O₂ 
• 887198-35-8 C₂₅H₃₅N₃O₂ 

Relevant academic research and scientific papers

Inhibition of Ebola virus infection: Identification of niemann-pick C1 as the target by optimization of a chemical probe

A high-throughput screen identified adamantane dipeptide 1 as an inhibitor of Ebola virus (EboV) infection. Hit-to-lead optimization to determine the structure-activity relationship (SAR) identified the more potent EboV inhibitor 2 and a photoaffinity labeling agent 3. These antiviral compounds were employed to identify the target as Niemann-Pick C1 (NPC1), a host protein that binds the EboV glycoprotein and is essential for infection. These studies establish NPC1 as a promising target for antiviral therapy.

From tyrosine to glycine: Synthesis and biological activity of potent antagonists of the purinergic P2X7 receptor

The characterization of the native and recombinant P2X7 receptor continues to be hindered by the lack of specific and subtype-selective antagonists with a "druglike" profile. However, a tyrosine derivative named KN-62 exhibits selective P2Xsub

Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors

Starting from the 3-[2-(1-benzylpiperidin-4-yl)ethylamino]-6-phenylpyridazine 1, we performed the design, the synthesis, and the structure-activity relationships of a series of pyridazine analogues acting as AChE inhibitors. Structural modifications were achieved on four different parts of compound 1 and led to the following observations: (i) introduction of a lipophilic environment in the C-5 position of the pyridazine ring is favorable for the AChE-inhibitory activity and the AChE/BuChE selectivity; (ii) substitution and various replacements of the C-6 phenyl group are possible and led to equivalent or slightly more active derivatives; (iii) isosteric replacements or modifications of the benzylpiperidine moiety are detrimental to the activity. Among all derivatives prepared, the indenopyridazine derivative 4g was found to be the more potent inhibitor with an IC50 of 10 nM on electric eel AChE. Compared to compound 1, this represents a 12-fold increase in potency. Moreover, 3-[2-(1-benzylpiperidin-4-yl)ethylamino]-5-methyl-6-phenylpyridazine 4c, which showed an IC50 of 21 nM, is 100-times more selective for human AChE (human BuChE/AChE ratio of 24) than the reference compound tacrine.